e Ertapenem is active against extended-spectrum-␤-lactamase (ESBL)-producing Enterobacteriaceae organisms but inactive against Pseudomonas aeruginosa and Acinetobacter baumannii. Due to a lack of therapeutic data for ertapenem in the treatment of ESBL bloodstream infections (BSIs), group 2 carbapenems (e.g., imipenem or meropenem) are often preferred for treatment of ESBL-producing Enterobacteriaceae, although their antipseudomonal activity is unnecessary. From 2005 to 2010, 261 patients with ESBL BSIs were analyzed. Outcomes were equivalent between patients treated with ertapenem and those treated with group 2 carbapenems (mortality rates of 6% and 18%, respectively; P ‫؍‬ 0.18).
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E
xtended-spectrum-␤-lactamase (ESBL)-producing Enterobacteriaceae organisms are recognized as an imminent threat to public health (7, 26) . No prospective, randomized, controlled trials have been conducted analyzing the preferred therapeutic management of ESBL-producing Enterobacteriaceae infections. Few small retrospective trials have demonstrated the relative superiority of carbapenems over other agents (4, 8, 12, 14, 17, 19, 21, 24, 31) . The carbapenems that were studied were group 2 carbapenems (e.g., imipenem and meropenem). Ertapenem is a group 1 carbapenem with no appreciable activity versus Pseudomonas aeruginosa and Acinetobacter baumannii (13) . Unfortunately, there are limited data pertaining to the efficacy of ertapenem for the treatment of serious invasive infections, such as bloodstream infections (BSIs), that are due to ESBL-producing Enterobacteriaceae (2, 3, 6, 10, 13, 22, 23, (27) (28) (29) (30) . Due to a lack of data, many clinicians rely on group 2 carbapenems for treatment of severe ESBL infections. A recent, commonly cited expert opinion review article did not even mention ertapenem as an option for the treatment of BSIs due to ESBL-producing Enterobacteriaceae (25) . This study aimed to compare the efficacies of group 1 carbapenems and group 2 carbapenems for the treatment of BSIs due to ESBL-producing Enterobacteriaceae.
A retrospective cohort study from 1 January 2005 to 30 June 2010 pertaining to outcomes of ESBL-producing Escherichia coli and Klebsiella pneumoniae BSIs was conducted at the Detroit Medical Center (DMC) health system after institutional review board approvals. Only unique adult (Ͼ18 years old) patient episodes were included. BSIs were defined according to CDC and systemic inflammatory response syndrome (SIRS) criteria (11, 15) . Polymicrobial infectious episodes were excluded. The time to initiation of appropriate therapy was captured in hours. Empirical regimens (antimicrobials administered from 48 h before to 71 h after the culture) and consolidative regimens (antimicrobials administered 72 h to 14 days following the culture) were reviewed. Only drugs for which Ն2 doses were administered were included as treatment agents. Outcomes captured included in-hospital and 3-month mortality, length of hospital stay (LOS), deterioration in functional status (18) , discharge to a long-term care facility (LTCF) after being admitted from home, additional hospitalization in the 6 months following discharge, and additional isolations of the same organism in the 3 months following the culture date (i.e., "bacteriologic failures"). Bacteria were identified to the species level, and susceptibilities to predefined antimicrobials were determined based on an automated broth microdilution system (MicroScan; Siemens AG, Germany) and in accordance with the CLSI criteria (9) . For representative isolates, a positive ESBL test from the automated system was confirmed with disc diffusion tests (9) . All analyses were performed using IBM SPSS 19 (2011). Logistic regression was used for multivariate analyses. Variables chosen for the model were based on clinical importance and the results of bivariate analyses between relevant groups (variables with a P value of Յ0.05). Variables with a P value of Յ0.05 were included in the final model and were adjusted for confounds. A propensity score analysis was conducted to establish the likelihood of receiving ertapenem and incorporated into outcome models.
The study cohort included 261 unique patients with BSIs due to ESBL-producing Enterobacteriaceae ( Table 1) . The majority of patients were elderly (53.6%), and 71% had a permanent device present for at least 48 h prior to ESBL-producing Enterobacteriaceae isolation. Most BSIs were from a urinary source (n ϭ 108 [41.4%]), and 51 (19.5%) were primary BSIs. Rates of resistance to other antimicrobial agents were high. No resistance to group 2 carbapenems was noted, but two cases (9.5%) were resistant to ertapenem (9) . Sixty-nine patients died in the hospital (26.4%), and 85 patients died within 90 days (38.3%). In multivariate analysis, in-hospital mortality was significantly lower among patients who received carbapenems in their consolidative regimen (n ϭ 181) than among those who received other in vitro active agents (14.9% versus 30%, respectively; adjusted OR ϭ 0.39 [95% confidence interval {CI} ϭ 0.16 to 0.95]; P ϭ 0.04). The association remained unchanged when patients who died early in the course of the disease were removed from analysis (in order to control for a potential selection bias). An analysis was conducted comparing subjects who received ertapenem for empirical treatment (n ϭ 24) to those who received empirical therapy with group 2 carbapenems (n ϭ 103) after excluding patients who received both and those for whom the blood culture results were returned postmortem. Cases receiving ertapenem were significantly more likely to have a BSI secondary to E. coli (P ϭ 0.05). Twenty-three patients (89%) receiving ertapenem had a low sepsis level, compared to 68 of subjects (66.7%) receiving a group 2 carbapenem (P ϭ 0.03). The mean time to initiation of effective therapy was significantly longer in subjects receiving ertapenem than in patients receiving a group 2 carbapenem (59 h and 42.5 h, respectively; P ϭ 0.04). In-hospital mortality occurred in 3 subjects (12%) treated empirically with ertapenem and 21 patients (20.4%) treated empirically with a group 2 carbapenem (OR ϭ 0.51 [95% CI ϭ 0.14 to 1.86]). Three-month mortality, deterioration in functional status, length of hospital stay, and other outcome measures demonstrated nonsignificant differences across the treatment groups. Sepsis level was the only variable which remained a significant predictor of in-hospital mortality (P Ͻ 0.005). Compared to group 2 carbapenem therapy, empirical therapy with ertapenem was not associated with in-hospital mortality in a multivariate analysis (adjusted OR ϭ 0.82 [95% CI ϭ 0.17 to 3.81]; P ϭ 0.79) controlling for the McCabe score, Charlson's weighted index comorbidity score, sepsis level, bacteremia source, time to effective therapy, or bacterium type. Similarly, 3-month mortality was not affected by carbapenem group (adjusted OR ϭ 1.64 [95% CI ϭ 0.23 to 11.49]; P ϭ 0.62). Sepsis level, McCabe score at admission, Charlson's weighted index comorbidity score, bacteremia source, and receipt of empirical fluoroquinolones were significantly associated with 3-month mortality in a multivariate analysis.
Seventy-two patients received ertapenem for consolidative therapy, and 132 received group 2 carbapenems. After excluding patients who received both types of carbapenems, the comparative analysis included 49 patients who received ertapenem and 109 patients who received a group 2 carbapenem (Table 2) . Subjects in the two groups had similar severities of illness (5) . Patients receiving ertapenem were significantly more likely to have bacteremia from a urinary source (P ϭ 0.01) and to have E. coli ESBL infection (P ϭ 0.001). The length of hospital stay prior to ESBL-producing Enterobacteriaceae isolation was shorter in patients receiving ertapenem (P ϭ 0.002), and patients receiving ertapenem were less likely to have been in the intensive care unit (ICU) prior to culture d Defined as having Acinetobacter baumannii or Pseudomonas aeruginosa isolated in the period between 7 days before and 7 days after the isolation of the Enterobacteriaceae. e Glucocorticoid therapy within the past month, anti-tumor necrosis factor ␣ therapy in the past 6 months, chemotherapy or radiotherapy in the past 3 months, or HIV, a posttransplantation status, or neutropenia (white blood cell count Ͻ 500) at culture date. f Expected to die within 2 months.
(P ϭ 0.005). Severe levels of sepsis, per SIRS criteria, were significantly less common in the ertapenem-treated group than in the group 2 carbapenem-treated group (10% versus 33.3%, respectively; OR ϭ 0.23; P ϭ 0.002). In-hospital mortality occurred in three (6.1%) patients treated with ertapenem consolidative therapy and in 20 (18.3%) of the patients treated with group 2 carbapenems (P ϭ 0.05) ( Table 3) . Mortality occurred within 90 days in six (15.8%) patients treated with ertapenem and in 31 (33.3%) patients treated with a group 2 carbapenem (P ϭ 0.05). In a multivariate analysis, the type of carbapenem (group 1 versus group 2) was not associated with increased mortality (adjusted OR ϭ 0.26; P ϭ 0.12). Adjusted predictors of mortality included the severity of sepsis (P Ͻ 0.005) and the McCabe score at admission. After controlling for a propensity score of receiving ertapenem consolidative therapy, ertapenem was not associated with increased risk for death (OR ϭ 0.50 [95% CI ϭ 0.12 to 2.1]; P ϭ 0.34). Similar results were noted for 90-day mortality in multivariate analyses utilizing a propensity score (OR ϭ 0.51 [95% CI ϭ 0.17 to 1.55]; P ϭ 0.23) and those not using a propensity score (adjusted OR ϭ 0.40; P ϭ 0.25). Severe sepsis, the McCabe score at admission, and Charlson's index were significantly associated with 90-day mortality. In a subanalysis restricted to patients with severe sepsis (n ϭ 41), three of five patients who received ertapenem as the main therapy died during the hospital stay (60%), compared to 13 of 36 patients who received group 2 carbapenems (36.1%) (P ϭ 0.36).
There are no strict guidelines or policies pertaining to the preferred therapeutic management of infections due to ESBL-producing Enterobacteriaceae, although many consider carbapenems the preferred agents (1, 4, 8, 12, 14, 17, 19, 21, 24, 31) . Among carbapenems, particularly for severe infections, many clinicians prefer to use a group 2 carbapenem rather than ertapenem (25) . In this large cohort of patients with ESBL BSIs, carbapenems were associated with significantly better clinical outcomes than other antimicrobial classes, a result which is similar to findings of other investigators (8, 12, 17, 19, 21, 24, 31) . Of particular interest, ertapenem was as effective as group 2 carbapenems in the treatment of ESBL BSIs. Although ertapenem was used for patients with less-invasive disease states and less-severe levels of sepsis, in multivariate and subgroup analyses controlling for differences in disease state and severity, ertapenem was as effective as group 2 carbapenems. It is notable that the study cohort consisted only of patients who had SIRS coupled with BSI. In terms of antimicrobial stewardship efforts geared toward limiting the emergence of carbapenem resistance among Pseudomonas aeruginosa, Acinetobacter baumannii, and Enterobacteriaceae, ertapenem should be considered an option for the treatment of ESBL BSIs. The findings in this study are consistent with previously published case series (3).
Although rare, reports of ESBL-producing Enterobacteriaceae with various levels of resistance to ertapenem have recently been published (16, 20) . In the study cohort, according to 2009 CLSI breakpoints, two isolates (9.5%) were resistant to ertapenem (9) .
The likelihood that a prospective, randomized, controlled trial that compares ertapenem and group 2 carbapenems for treatment of invasive infections due to ESBLs will be conducted in the near future is low. This large retrospective study provides the best available evidence to date regarding the efficacy of ertapenem in the treatment of ESBL BSIs. Based on these results, ertapenem should be considered a viable therapeutic option. Its relatively narrow spectrum of activity compared to that of other carbapenems is attractive from both antimicrobial stewardship and infection control perspectives. 
